Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | standudu |
|---|---|
| Group name | EquipeAM |
| Item Type | Attachment |
| Title | PubMed entry |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/30664989 |
| Accessed | 2019/05/16 - 13:44:19 |
| Date Added | 2019/05/16 - 11:44:19 |
| Date Modified | 2019/05/16 - 11:44:19 |
| Parent item | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de